Plonmarlimab clinical trials
Also written TJ003234.
How each study uses plonmarlimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the plonmarlimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 2 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test plonmarlimab, phase 3 first.
- Dec 2026A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])Phase 3 · TJ Biopharma Co., Ltd.
Studies
Open first, then newest update. How each study uses plonmarlimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty ArthritisRecruitingPhase 2TJ Biopharma Co., Ltd.NCT07453004Written as Plonmarlimab
- A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])RecruitingPhase 3TJ Biopharma Co., Ltd.NCT07208058Written as Plonmarlimab
- A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))CompletedPhase 2TJ Biopharma Co., Ltd.NCT07034209Written as Plonmarlimab
- Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)CompletedPhase 2/3I-Mab Biopharma US LimitedNCT04341116Written as TJ003234
- A Study of TJ003234 in Rheumatoid Arthritis PatientsStatus unknownPhase 1I-Mab Biopharma US LimitedNCT04457856Written as TJ003234 injection
- Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Healthy Adult SubjectsCompletedPhase 1I-Mab Biopharma US LimitedNCT03794180Written as TJ003234
Codes
What other systems call plonmarlimab · ClinicalTrials.gg INT001481
- MeSH (NLM) C000711830plonmarlimabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) M1K0A3X96WPLONMARLIMABConfirmed FDA, NLM
- NCI Thesaurus C172653PlonmarlimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000711830 | plonmarlimab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | M1K0A3X96W | PLONMARLIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C172653 | Plonmarlimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.